Johnson & Johnson (JNJ) stock is drawing fresh attention after the FDA granted Priority Review to IMAAVY for warm autoimmune hemolytic anemia and approved a new CAPLYTA label for relapse prevention in schizophrenia.

Despite a series of recent FDA milestones and product updates across rare disease and neuropsychiatry, Johnson & Johnson’s 30 day share price return of 7.75% and 90 day share price return of 3.82% suggest fading short term momentum, while the 1 year total shareholder return of 48.68% points to stronger longer term performance.

If this kind of healthcare news has your attention, it may be a good moment to see what else is moving in the sector through a focused screener for 33 healthcare AI stocks

Johnson & Johnson now trades at a reported 40% intrinsic discount and about 13% below the average analyst price target. Yet recent short term returns are soft, so is the stock still mispriced or are markets already baking in future growth?

Most Popular Narrative: 29.2% Overvalued

Johnson & Johnson last closed at $224.20, while the most followed narrative on Simply Wall St assigns a fair value of $173.55, creating a clear gap between market price and that valuation anchor.

Post Kenvue, I expect JNJ to grow revenues by 7.5% p.a. from its new baseline of $84B, and at higher margins.

Curious how that revenue path and margin profile support a value below today’s price? The narrative leans on specific growth rates, profit assumptions and a future earnings multiple that together do the heavy lifting in this fair value view.

Result: Fair Value of $173.55 (OVERVALUED)

However, the narrative could be challenged if litigation costs or weaker than expected margins in Innovative Medicine and MedTech keep profit levels below the assumed 20% target.

Another View: Cash Flows Point the Other Way

The user narrative leans on earnings and a future P/E of 22x to argue that Johnson & Johnson is 29.2% overvalued, with fair value at $173.55 per share. In contrast, Simply Wall St’s DCF model, which focuses on forecast cash flows, suggests the stock is trading at a 40.5% discount to its estimated future cash flow value of $376.56.

Two valuation anchors, one pointing to overvaluation and one to a sizable discount, leave you with a practical question: which set of assumptions around growth, margins and cash conversion feels more realistic for your own thesis?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on value and sentiment, this is a good time to move fast, review the underlying numbers yourself, and weigh the trade off between upside and risk using the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop with Johnson & Johnson. Broaden your watchlist now so you are not relying on a single story when the next opportunity appears.

• Target reliable income by scanning for companies that keep paying investors through thick and thin using the 12 dividend fortresses.
• Hunt for quality at a discount by checking the 48 high quality undervalued stocks that combine solid fundamentals with appealing price tags.
• Reduce portfolio stress by focusing on resilience first through the 70 resilient stocks with low risk scores that prioritise financial strength and stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.